SCHEMBL2621820

SCHEMBL2621820

Ic1ccc2nccc(OC[C@@H]3CCCN(CCN4CCOCC4)C3)c2c1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDPK1 O15530 3/20 0.49
▸ HTR1A P08908 1/20 0.41
▸ PRKDC P78527 4/20 0.39
▸ IRAK4 Q9NWZ3 4/20 0.37
▸ AXL P30530 1/20 0.37
▸ KCNH2 Q12809 2/20 0.37
▸ HTR4 Q13639 2/20 0.37
▸ CCNT1 O60563 1/20 0.36
▸ CDK9 P50750 1/20 0.36
▸ PIK3CD O00329 1/20 0.36
▸ PIK3R1 P27986 1/20 0.36
▸ KDR P35968 1/20 0.36
▸ USP2 O75604 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ CLK4 Q9HAZ1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2621822 0.84 ROCK2 (0.47) PDPK1IRAK4KDR
SCHEMBL2621818 0.73 IRAK4 (0.56) PDPK1IRAK4KCNH2
SCHEMBL2621821 0.69 PDPK1 (0.47) PDPK1IRAK4KCNH2KDRCYP2D6
SCHEMBL2621813 0.67 IRAK4 (0.46) PDPK1IRAK4KCNH2
SCHEMBL19723307 0.67 EGFR (0.46) PDPK1IRAK4AXLKCNH2KDR
SCHEMBL2621812 0.67 EGFR (0.46) PDPK1IRAK4AXLKCNH2KDR
SCHEMBL2621811 0.67 EGFR (0.46) PDPK1IRAK4AXLKCNH2KDR
SCHEMBL2621815 0.66 IRAK4 (0.48) PDPK1IRAK4CLK4
SCHEMBL12285582 0.65 GAK (0.61) —
SCHEMBL5501482 0.65 IRAK4 (0.49) IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2560967-B1 Heterocyclic carboxylic acid amides as PDK1 inihibitors BOEHRINGER INGELHEIM INT (DE) 2017-12-20 — — EP disclosed
US-8575203-B2 Chemical compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-11-05 — — US disclosed
US-8575203-B2 Chemical compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-11-05 — — US disclosed
US-20120094976-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-19 — — US disclosed
US-20120094976-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-19 — — US disclosed
WO-2011131741-A1 HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094976-A1 NEW CHEMICAL COMPOUNDS CCNB1, MKI67, CCNA1 PDPK1 1873/4885HTR1A 754/4885PRKDC 4618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback